PMID- 17303115
OWN - NLM
STAT- MEDLINE
DCOM- 20070515
LR  - 20131121
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 560
IP  - 1
DP  - 2007 Mar 29
TI  - Effect of NC-1900, an active fragment analog of arginine vasopressin, and 
      inhibitors of arachidonic acid metabolism on performance of a passive avoidance 
      task in mice.
PG  - 36-41
AB  - In this study, we investigated the effect of administration of inhibitors of each 
      of the arachidonic acid metabolism pathways and the effect of co-administration 
      of these inhibitors with NC-1900, a fragment analog of arginine vasopressin, on 
      step-through passive avoidance task performance. All drugs were administered just 
      after the acquisition trial in the passive avoidance task. 
      Intracerebroventricular (i.c.v.) administration of nordihydroguaiaretic acid 
      (NDGA, 1 and 10 microg), a phospholipase A2 (PLA2) and lipoxygenase (LOX) 
      inhibitor, and of arachidonyl trifluoromethyl ketone (ATK, 1 and 10 microg), a 
      specific PLA2 inhibitor caused reductions in latency on the retention trial. The 
      i.c.v. administration of either of baicalein (0.1-10 microg), a 12-LOX inhibitor, 
      or AA-861 (0.1-10 microg), a 5-LOX inhibitor, did not influence the latency. 
      Intraperitoneal administration of indomethacin (20 mg/kg), a non-specific COX 
      inhibitor, or NS-398 (10 mg/kg), a specific COX-2 inhibitor, impaired performance 
      on the retention trial in the task, while piroxicam (20 mg/kg), a specific COX-1 
      inhibitor, did not. Subcutaneous administration of NC-1900 (0.1 ng/kg) 
      ameliorated the reduction of latency caused by NDGA, ATK, indomethacin, or 
      NS-398. These results suggested that the COX-2 pathway of arachidonic acid 
      metabolism may be important for learning and/or memory in the passive avoidance 
      task in mice, and that the ameliorating effect of NC-1900, in part, is due to 
      mimicking of the effects of metabolites of the COX-2 pathway.
FAU - Sato, Tomoaki
AU  - Sato T
AD  - Department of Applied Pharmacology, Kagoshima University Graduate School of 
      Medical and Dental Sciences, Sakuragaoka-8, Kagoshima 890-8544, Japan. 
      tomsato@dentb.hal.kagoshima-u.ac.jp
FAU - Ishida, Takayuki
AU  - Ishida T
FAU - Irifune, Masahiro
AU  - Irifune M
FAU - Tanaka, Koh-ichi
AU  - Tanaka K
FAU - Hirate, Kenji
AU  - Hirate K
FAU - Nakamura, Norifumi
AU  - Nakamura N
FAU - Nishikawa, Takashige
AU  - Nishikawa T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070119
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (NC 1900)
RN  - 0 (Oligopeptides)
RN  - 113-79-1 (Arginine Vasopressin)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - SZB83O1W42 (Pyrrolidonecarboxylic Acid)
SB  - IM
MH  - Amnesia/chemically induced/*drug therapy
MH  - Animals
MH  - Arachidonic Acid/antagonists & inhibitors/*metabolism
MH  - Arginine Vasopressin/analogs & derivatives/physiology
MH  - Avoidance Learning/*drug effects
MH  - Cyclooxygenase 2/drug effects/metabolism
MH  - Enzyme Inhibitors/pharmacology
MH  - Injections, Intraperitoneal
MH  - Injections, Intraventricular
MH  - Male
MH  - Memory/*drug effects
MH  - Mice
MH  - Oligopeptides/*pharmacology/therapeutic use
MH  - Pyrrolidonecarboxylic Acid/*analogs & derivatives/pharmacology/therapeutic use
EDAT- 2007/02/17 09:00
MHDA- 2007/05/16 09:00
CRDT- 2007/02/17 09:00
PHST- 2006/10/24 00:00 [received]
PHST- 2006/12/27 00:00 [revised]
PHST- 2007/01/08 00:00 [accepted]
PHST- 2007/02/17 09:00 [pubmed]
PHST- 2007/05/16 09:00 [medline]
PHST- 2007/02/17 09:00 [entrez]
AID - S0014-2999(07)00025-8 [pii]
AID - 10.1016/j.ejphar.2007.01.011 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2007 Mar 29;560(1):36-41. doi: 10.1016/j.ejphar.2007.01.011. 
      Epub 2007 Jan 19.